Precision respiratory medicine and the microbiome

The Lancet Respiratory Medicine

Volumn 4, Issue 1, 2016, Pages 73-82

  Rogers, Geraint B ^a,b   Wesselingh, Steve ^a,b  

^a SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; HEALTH CARE; HUMAN; INFECTION RISK; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; MICROBIOME; NONHUMAN; PERSONALIZED MEDICINE; PHENOTYPE; PRACTICE GUIDELINE; PRECISION RESPIRATORY MEDICINE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY CARE; RESPIRATORY TRACT DISEASE; REVIEW; SCIENTIST; SIDE EFFECT; TREATMENT RESPONSE; LUNG; LUNG DISEASES; MICROBIOLOGY; MICROFLORA; PULMONOLOGY; RESPIRATORY SYSTEM; TRANSLATIONAL RESEARCH;

HUMANS; LUNG; LUNG DISEASES; MICROBIOTA; PRECISION MEDICINE; PULMONARY MEDICINE; RESPIRATORY SYSTEM; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84952988286     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00476-2     Document Type: Review

References (131)

1. Mendelsohn J Personalizing oncology: perspectives and prospects. J Clin Oncol 2013, 31:1904-1911.
2. Collins FS, Varmus H A new initiative on precision medicine. N Engl J Med 2015, 372:793-795.
3. Rogers GB, Carroll MP, Bruce KD Studying bacterial infections through culture-independent approaches. J Med Microbiol 2009, 58:1401-1418.
4. Patient registry: 2013 annual data report to the center directors, Bethesda, MD, USA Cystic Fibrosis Foundation, (accessed Nov 24, 2015). https://www.cff.org/2013_CFF_Annual_Data_Report_to_the_Center_Directors.pdf.
5. Van Goor F, Yu H, Burton B, Hoffman BJ Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 2014, 13:29-36.
6. Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014, 2:527-538. for the VX09-809-102 study group.
7. Collaco JM, Blackman SM, McGready J, Naughton KM, Cutting GR Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. J Pediatr 2010, 157:802-807. e1-3.
8. Wenzel SE Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012, 18:716-725.
9. Courtney JM, Bradley J, Mccaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007, 42:525-532.
10. Wei C, Cheng Z, Zhang L, Yang J Microbiology and prognostic factors of hospital- and community-acquired aspiration pneumonia in respiratory intensive care unit. Am J Infect Control 2013, 41:880-884.
11. Wolter DJ, Emerson JC, McNamara S, et al. Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. Clin Infect Dis 2013, 57:384-391.
12. Hurley MN, Ariff AH, Bertenshaw C, Bhatt J, Smyth AR Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J Cyst Fibros 2012, 11:288-292.
13. Mayer-Hamblett N, Rosenfeld M, Gibson RL, et al. Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. Am J Respir Crit Care Med 2014, 190:289-297.
14. Rogers GB, Hoffman LR, Whiteley M, Daniels TW, Carroll MP, Bruce KD Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy. Trends Microbiol 2010, 18:357-364.
15. Structure, function and diversity of the healthy human microbiome. Nature 2012, 486:207-214. Human Microbiome Project Consortium.
16. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 2012, 486:222-227.
17. Grice EA, Segre JA The skin microbiome. Nat Rev Microbiol 2011, 9:244-253.
18. Stringer AM, Al-Dasooqi N, Bowen JM, et al. Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer 2013, 21:1843-1852.
19. Kang SS, Jeraldo PR, Kurti A, et al. Diet and exercise orthogonally alter the gut microbiome and reveal independent associations with anxiety and cognition. Mol Neurodegener 2014, 9:36.
20. Allen JM, Berg Miller ME, Pence BD, et al. Voluntary and forced exercise differentially alters the gut microbiome in C57BL/6J mice. J Appl Physiol (1985) 2015, 118:1059-1066.
21. Neish AS Mucosal immunity and the microbiome. Ann Am Thorac Soc 2014, 11(suppl 1):S28-S32.
22. Nieuwdorp M, Gilijamse PW, Pai N, Kaplan LM Role of the microbiome in energy regulation and metabolism. Gastroenterology 2014, 146:1525-1533.
23. Lyte M Microbial endocrinology in the microbiome-gut-brain axis: how bacterial production and utilization of neurochemicals influence behavior. PLoS Pathog 2013, 9:e1003726.
24. Jacobs JP, Braun J Immune and genetic gardening of the intestinal microbiome. FEBS Lett 2014, 588:4102-4111.
25. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI Human nutrition, the gut microbiome and the immune system. Nature 2011, 474:327-336.
26. Rakoff-Nahoum S, Medzhitov R Innate immune recognition of the indigenous microbial flora. Mucosal Immunol 2008, 1(suppl 1):S10-S14.
27. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
28. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
29. Zhang X, Zhang D, Jia H, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med 2015, 21:895-905.
30. Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci 2014, 34:15490-15496.
31. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011, 184:957-963.
32. Morris A, Beck JM, Schloss PD, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med 2013, 187:1067-1075. the Lung HIV Microbiome Project.
33. Venkataraman A, Bassis CM, Beck JM, et al. Application of a neutral community model to assess structuring of the human lung microbiome. MBio 2015, 6:e02284-e02314.
34. Rogers GB, Shaw D, Marsh RL, Carroll MP, Serisier DJ, Bruce KD Respiratory microbiota: addressing clinical questions, informing clinical practice. Thorax 2015, 70:74-81.
35. Rogers GB, Hoffman LR, Carroll MP, Bruce KD Interpreting infective microbiota: the importance of an ecological perspective. Trends Microbiol 2013, 21:271-276.
36. van der Gast CJ, Cuthbertson L, Rogers GB, et al. Three clinically distinct chronic pediatric airway infections share a common core microbiota. Ann Am Thorac Soc 2014, 11:1039-1048.
37. Rudkjøbing VB, Thomsen TR, Alhede M, et al. The microorganisms in chronically infected end-stage and non-end-stage cystic fibrosis patients. FEMS Immunol Med Microbiol 2012, 65:236-244.
38. Rogers GB, Zain NM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014, 11:496-503.
39. Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2014, 2:548-556. the COMET Investigators.
40. Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1073-1080.
41. Binder AM, Adjemian J, Olivier KN, Prevots DR Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013, 188:807-812.
42. Short FL, Murdoch SL, Ryan RP Polybacterial human disease: the ills of social networking. Trends Microbiol 2014, 22:508-516.
43. Ryan RP, Fouhy Y, Garcia BF, et al. Interspecies signalling via the Stenotrophomonas maltophilia diffusible signal factor influences biofilm formation and polymyxin tolerance in Pseudomonas aeruginosa. Mol Microbiol 2008, 68:75-86.
44. Duan K, Dammel C, Stein J, Rabin H, Surette MG Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol Microbiol 2003, 50:1477-1491.
45. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci USA 2008, 105:15070-15075.
46. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012, 487:109-113.
47. Bartowsky EJ, Henschke PA The 'buttery' attribute of wine-diacetyl-desirability, spoilage and beyond. Int J Food Microbiol 2004, 96:235-252.
48. Palmer KL, Aye LM, Whiteley M Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum. J Bacteriol 2007, 189:8079-8087.
49. Venkataraman A, Rosenbaum AM, Perkins SD, et al. Metabolite-based mutualism between Pseudomonas aeruginosa PA14 and Enterobacter aerogenes enhances current generation in bioelectrochemical systems. Energy Environ Sci 2011, 4:4550-4559.
50. Venkataraman A, Rosenbaum MA, Werner JJ, Winans SC, Angenent LT Metabolite transfer with the fermentation product 2,3-butanediol enhances virulence by Pseudomonas aeruginosa. ISME J 2014, 8:1210-1220.
51. Rogers GB, Carroll MP, Hoffman LR, Walker AW, Fine DA, Bruce KD Comparing the microbiota of the cystic fibrosis lung and human gut. Gut Microbes 2010, 1:85-93.
52. Sibley CD, Duan K, Fischer C, et al. Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections. PLoS Pathog 2008, 4:e1000184.
53. Whiteson KL, Meinardi S, Lim YW, et al. Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation. ISME J 2014, 8:1247-1258.
54. Dickson RP, Martinez FJ, Huffnagle GB The role of the microbiome in exacerbations of chronic lung diseases. Lancet 2014, 384:691-702.
55. Donaldson GC, Law M, Kowlessar B, et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015, 192:943-950.
56. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 188:1224-1231.
57. Shimizu K, Yoshii Y, Morozumi M, et al. Pathogens in COPD exacerbations identified by comprehensive real-time PCR plus older methods. Int J Chron Obstruct Pulmon Dis 2015, 10:2009-2016.
58. Chin M, De Zoysa M, Slinger R, et al. Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations. J Cyst Fibros 2015, 14:482-489.
59. Plummer A, Wildman M Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev 2013, 5. CD006682.
60. VanDevanter DR, O'Riordan MA, Blumer JL, Konstan MW Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res 2010, 11:137.
61. Falagas ME, Avgeri SG, Matthaiou DK, Dimopoulos G, Siempos II Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother 2008, 62:442-450.
62. Waters V, Stanojevic S, Klingel M, et al. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. J Cyst Fibros 2015, 14:770-776.
63. Smith JA, Redman P, Woodhead MA Antibiotic use in patients admitted with acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1999, 13:835-838.
64. Smith DJ, Badrick AC, Zakrzewski M, et al. Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. Eur Respir J 2014, 44:922-930.
65. Daniels TWV, Rogers GB, Stressmann FA, et al. Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis. J Cyst Fibros 2013, 12:22-28.
66. Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA 2012, 109:5809-5814.
67. Salsgiver EL, Fink AK, Knapp EA, et al. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis. Chest 2015, published online July 23. 10.1378/chest.15-0676.
68. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013, 309:1260-1267.
69. Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med 2014, 2:988-996.
70. Rogers GB, van der Gast CJ, Serisier DJ Predominant pathogen competition and core microbiota divergence in chronic airway infection. ISME J 2015, 9:217-225.
71. McKeever T, Harrison TW, Hubbard R, Shaw D Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study. Chest 2013, 144:1788-1794.
72. Llewellyn-Jones CG, Hill SL, Stockley RA Effect of fluticasone propionate on neutrophil chemotaxis, superoxide generation, and extracellular proteolytic activity in vitro. Thorax 1994, 49:207-212.
73. Green BJ, Wiriyachaiporn S, Grainge C, et al. Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. PLoS One 2014, 9:e100645.
74. Deshmukh HS, Liu Y, Menkiti OR, et al. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nat Med 2014, 20:524-530.
75. Rooney C, Sethi T Biomarkers for precision medicine in airways disease. Ann N Y Acad Sci 2015, 1346:18-32.
76. Brightling CE Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2013, 10(suppl):S214-S219.
77. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300:2407-2416.
78. Suissa S, Coulombe J, Ernst P Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest 2015, 148:1177-1183.
79. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012, 12. CD010257.
80. Garcia-Nuñez M, Millares L, Pomares X, et al. Severity-related changes of bronchial microbiome in chronic obstructive pulmonary disease. J Clin Microbiol 2014, 52:4217-4223.
81. Dickson RP, Erb-Downward JR, Huffnagle GB The role of the bacterial microbiome in lung disease. Expert Rev Respir Med 2013, 7:245-257.
82. Sze MA, Dimitriu PA, Suzuki M, et al. Host response to the lung microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015, 192:438-445.
83. Cox MJ, Moffatt MF, Cookson WO Outside in: sequencing the lung microbiome. Am J Respir Crit Care Med 2015, 192:403-404.
84. Huang YJ, Sethi S, Murphy T, Nariya S, Boushey HA, Lynch SV Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol 2014, 52:2813-2823.
85. Rogers GB The human microbiome: opportunities and challenges for clinical care. Intern Med J 2015, 45:889-898.
86. McDermott AJ, Huffnagle GB The microbiome and regulation of mucosal immunity. Immunology 2014, 142:24-31.
87. Round JL, Mazmanian SK The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009, 9:313-323.
88. Clarke TB Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands. Infect Immun 2014, 82:4596-4606.
89. Karmarkar D, Rock KL Microbiota signalling through MyD88 is necessary for a systemic neutrophilic inflammatory response. Immunology 2013, 140:483-492.
90. Abt MC, Osborne LC, Monticelli LA, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 2012, 37:158-170.
91. Hansson J, Bosco N, Favre L, et al. Influence of gut microbiota on mouse B2 B cell ontogeny and function. Mol Immunol 2011, 48:1091-1101.
92. Ma J, Prince AL, Bader D, et al. High-fat maternal diet during pregnancy persistently alters the offspring microbiome in a primate model. Nat Commun 2014, 5:3889.
93. Groer MW, Luciano AA, Dishaw LJ, Ashmeade TL, Miller E, Gilbert JA Development of the preterm infant gut microbiome: a research priority. Microbiome 2014, 2:38.
94. Huang YJ, Nariya S, Harris JM, et al. The airway microbiome in patients with severe asthma: Associations with disease features and severity. J Allergy Clin Immunol 2015, 136:874-884.
95. Björkstén B, Sepp E, Julge K, Voor T, Mikelsaar M Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001, 108:516-520.
96. Kalliomäki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001, 107:129-134.
97. Arrieta MC, Stiemsma LT, Dimitriu PA, et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci Transl Med 2015, 7:307ra152.
98. Kuppala VS, Meinzen-Derr J, Morrow AL, Schibler KR Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr 2011, 159:720-725.
99. Cox LM, Yamanishi S, Sohn J, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 2014, 158:705-721.
100. Merenstein DJ, Gatti ME, Mays DM The association of mode of delivery and common childhood illnesses. Clin Pediatr (Phila) 2011, 50:1024-1030.
101. Sun W, Svendsen ER, Karmaus WJ, Kuehr J, Forster J Early-life antibiotic use is associated with wheezing among children with high atopic risk: a prospective European study. J Asthma 2015, 52:647-652.
102. Biesbroek G, Tsivtsivadze E, Sanders EA, et al. Early respiratory microbiota composition determines bacterial succession patterns and respiratory health in children. Am J Respir Crit Care Med 2014, 190:1283-1292.
103. McDermott DS, Weiss KA, Knudson CJ, Varga SM Central role of dendritic cells in shaping the adaptive immune response during respiratory syncytial virus infection. Future Virol 2011, 6:963-973.
104. Li SQ, Guthridge SL, d'Espaignet ET, et al. From infancy to young adulthood: health status in the Northern Territory 2006 2007, Department of Health and Community Services, Darwin, NT.
105. Pawlińska-Chmara R, Wronka I Assessment of the effect of socioeconomic factors on the prevalence of respiratory disorders in children. J Physiol Pharmacol 2007, 58(suppl 5):523-529.
106. McCuskee S, Kirlew M, Kelly L, Fewer S, Kovesi T Bronchiolitis and pneumonia requiring hospitalization in young first nations children in Northern Ontario, Canada. Pediatr Infect Dis J 2014, 33:1023-1026.
107. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004, 118:229-241.
108. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.
109. Wu HJ, Wu E The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes 2012, 3:4-14.
110. Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015, 161:264-276.
111. Fox CJ, Hammerman PS, Thompson CB Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 2005, 5:844-852.
112. Canfora EE, Jocken JW, Blaak EE Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol 2015, 11:577-591.
113. Kim CH, Park J, Kim M Gut microbiota-derived short-chain fatty acids, T cells, and inflammation. Immune Netw 2014, 14:277-288.
114. Willing BP, Russell SL, Finlay BB Shifting the balance: antibiotic effects on host-microbiota mutualism. Nat Rev Microbiol 2011, 9:233-243.
115. Pettigrew MM, Laufer AS, Gent JF, Kong Y, Fennie KP, Metlay JP Upper respiratory tract microbial communities, acute otitis media pathogens, and antibiotic use in healthy and sick children. Appl Environ Microbiol 2012, 78:6262-6270.
116. Allen EK, Koeppel AF, Hendley JO, Turner SD, Winther B, Sale MM Characterization of the nasopharyngeal microbiota in health and during rhinovirus challenge. Microbiome 2014, 2:22.
117. McNamee LA, Harmsen AG Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infect Immun 2006, 74:6707-6721.
118. Sakwinska O, Bastic Schmid V, Berger B, et al. Nasopharyngeal microbiota in healthy children and pneumonia patients. J Clin Microbiol 2014, 52:1590-1594.
119. de Steenhuijsen Piters WA, Sanders EA, Bogaert D The role of the local microbial ecosystem in respiratory health and disease. Philos Trans R Soc Lond B Biol Sci 2015, 370:20140294.
120. Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog 2013, 9:e1003057.
121. Luoto R, Ruuskanen O, Waris M, Kalliomäki M, Salminen S, Isolauri E Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial. J Allergy Clin Immunol 2014, 133:405-413.
122. Nakajima T, Palchevsky V, Perkins DL, Belperio JA, Finn PW Lung transplantation: infection, inflammation, and the microbiome. Semin Immunopathol 2011, 33:135-156.
123. Vanaudenaerde BM, Dupont LJ, Wuyts WA, et al. The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J 2006, 27:779-787.
124. Snell GI, Levvey BJ, Zheng L, et al. Interleukin-17 and airway inflammation: a longitudinal airway biopsy study after lung transplantation. J Heart Lung Transplant 2007, 26:669-674.
125. Shilling RA, Wilkes DS Role of Th17 cells and IL-17 in lung transplant rejection. Semin Immunopathol 2011, 33:129-134.
126. Abadja F, Sarraj B, Ansari MJ Significance of T helper 17 immunity in transplantation. Curr Opin Organ Transplant 2012, 17:8-14.
127. Medina M, Villena J, Salva S, Vintiñi E, Langella P, Alvarez S Nasal administration of Lactococcus lactis improves local and systemic immune responses against Streptococcus pneumoniae. Microbiol Immunol 2008, 52:399-409.
128. Tomosada Y, Chiba E, Zelaya H, et al. Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection. BMC Immunol 2013, 14:40.
129. Hardy H, Harris J, Lyon E, Beal J, Foey AD Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients 2013, 5:1869-1912.
130. Trompette A, Gollwitzer ES, Yadava K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 2014, 20:159-166.
131. Verleden GM Chronic allograft rejection (obliterative bronchiolitis). Semin Respir Crit Care Med 2001, 22:551-558.